Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Venous Thrombosis 1Venous Thromboembolism 1Upper Extremity Deep Vein Thrombosis 1Recurrence 1Lung Neoplasms 1Hemorrhage 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Brentuximab Vedotin 3relmacabtagene autoleucel 2fludarabine phosphate 2fludarabine 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 2xihuang 1tocilizumab 1tislelizumab 1sofosbuvir-velpatasvir drug combination 1sintilimab 1rasburicase 1ledipasvir 1entecavir 1apatinib 1aflibercept 1acalabrutinib 1Urate Oxidase 1Trabectedin 1Thiotepa 1Thalidomide 1Tenofovir 1Tamsulosin 1Sofosbuvir 1Sevoflurane 1Rivaroxaban 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recurrence × Rivaroxaban × Clear all
NCT01989845 2017-01-09

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Seoul National University Hospital

Phase 4 Completed
127 enrolled

Hemorrhage, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡